Supernus Pharmaceuticals Says FDA Grants Seven Years Orphan-Drug Exclusivity For Onapgo
Oct 21 (Reuters) - Supernus Pharmaceuticals, Inc. SUPN.O:
SUPERNUS PHARMACEUTICALS - FDA GRANTS SEVEN YEARS ORPHAN-DRUG EXCLUSIVITY FOR ONAPGO
Further company coverage: SUPN.O